Jimmy Orjala

Jimmy Orjala

Auto-generated profile, based on publicly available information

Jimmy Orjala

Department of Pharmaceutical Sciences, Retzky College of Pharmacy, University of Illinois, Chicago, Chicago, IL 60612, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
YGYukuang Guo
Yukuang Guo
CCCamila Manoel Crnkovic
Camila Manoel Crnkovic
KWKyoung-Jae Won
Kyoung-Jae Won
XYXiaotong Yang
Xiaotong Yang
JLJohn Richard Lee
John Richard Lee
HJHyunyoung Jeong
Hyunyoung Jeong
Tacrolimus exhibits low and variable drug exposure after oral dosing, but the contributing factors remain unclear. Based on our recent report showing a positive correlation between fecal abundance of Faecalibacterium prausnitzii and oral tacrolimus dose in kidney transplant patients, we tested whether F. prausnitzii and other gut abundant bacteria are capable of metabolizing tacrolimus. Incubation of F. prausnitzii with tacrolimus led to production of two compounds (the major one named M1), which was not observed upon tacrolimus incubation with hepatic microsomes. Isolation, purification, and structure elucidation using mass spectrometry and nuclear magnetic resonance spectroscopy indicated that M1 is a C-9 keto-reduction product of tacrolimus. Pharmacological activity testing using human peripheral blood mononuclear cells demonstrated that M1 is 15-fold less potent than tacrolimus as an immunosuppressant. Screening of 22 gut bacteria species revealed that most Clostridiales bacteria are extensive tacrolimus metabolizers. Tacrolimus conversion to M1 was verified in fresh stool samples from two healthy adults. M1 was also detected in the stool samples from kidney transplant recipients who had been taking tacrolimus orally. Together, this study presents gut bacteria metabolism as a previously unrecognized elimination route of tacrolimus, potentially contributing to the low and variable tacrolimus exposure after oral dosing.

16 April 2009 in Journal of Natural Products
Verified
Journal Article
Closed access
SMShunyan Mo
Shunyan Mo
AKAleksej Krunic
Aleksej Krunic
GCGeorge Chlipala
George Chlipala
JOJimmy Orjala
Jimmy Orjala

1 October 2011 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
GCGeorge E. Chlipala
George E. Chlipala
SMShunyan Mo
Shunyan Mo
JOJimmy Orjala
Jimmy Orjala
Cyanobacteria are considered a promising source for new pharmaceutical lead compounds and a large number of chemically diverse and bioactive metabolites have been obtained from cyanobacteria over the last few decades. This review highlights the structural diversity of natural products from freshwater and terrestrial cyanobacteria. The review is divided into three areas: cytotoxic metabolites, protease inhibitors, and antimicrobial metabolites. The first section discusses the potent cytotoxins cryptophycin and tolytoxin. The second section covers protease inhibitors from freshwater and terrestrial cyanobacteria and is divided in five subsections according to structural class: aeruginosins, cyanopeptolins, microviridins, anabaenopeptins, and microginins. Structure activity relationships are discussed within each protease inhibitor class. The third section, antimicrobial metabolites from freshwater and terrestrial cyanobacteria, is divided by chemical class in three subsections: alkaloids, peptides and terpenoids. These examples emphasize the structural diversity and drug development potential of natural products from freshwater and terrestrial cyanobacteria.

1 December 2010 in Phytochemistry
Verified
Journal Article
Closed access
SMShunyan Mo
Shunyan Mo
AKAleksej Krunic
Aleksej Krunic
BSBernard Santarsiero
Bernard Santarsiero
SFScott Franzblau
Scott Franzblau
JOJimmy Orjala
Jimmy Orjala

1 September 2012 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
HKHyunjung Kim
Hyunjung Kim
DLDaniel Lantvit
Daniel Lantvit
CHChang Hwa Hwang
Chang Hwa Hwang
DKDavid J. Kroll
David J. Kroll
SSSteven M. Swanson
Steven M. Swanson
JOJimmy Orjala
Jimmy Orjala

7 April 2010 in Journal of Natural Products
Verified
Journal Article
Closed access
GCGeorge E. Chlipala
George E. Chlipala
PTPham Huu Tri
Pham Huu Tri
NHNguyen Van Hung
Nguyen Van Hung
AKAleksej Krunic
Aleksej Krunic
SSSang Hee Shim
Sang Hee Shim
JOJimmy Orjala
Jimmy Orjala